Related Experiment Video
Updated: May 13, 2026

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
Published on: March 17, 2023
An overview of FDA regulatory requirements for new medical devices
Joseph F Sucher1, Stephen L Jones, Isaac D Montoya
1Assistant Professor of Surgery Weill Cornell Medical College, Division of Surgical Critical Care and Acute Care Surgery, Department of Surgery, 6550 Fannin Street Smith Tower 1661 Houston, TX 77030, USA.
Background:
US national healthcare expenditure reached over 2 trillion dollars in 2007. medical device expenditure has remained nearly a constant 6% of the total healthcare expenditure. medical technology may be one of the driving factors increasing healthcare costs. the number of medical device (which includes diagnostic tests) and laboratory equipment manufacturers, and investment in research for medical devices continue to rise. medical device manufacturers can receive a higher than average return on investment if they successfully navigate the food and drug administration (FDA) approval process.
Objective:
this paper focuses on the series of steps a manufacturer can pursue to facilitate the introduction of a new device to the us market.
Method:
a review of the FDA regulations and current literature was conducted.
Results/Conclusion:
exemption from a full review by the FDA owing to substantial equivalence is one of the pathways a manufacturer can pursue for quicker and easier approval of the new device. three classes of devices are reviewed, as are some of the key regulations governing them. the regulations for advertising and promotion are still unclear because of the gray area that exists between the federal trade commission and the FDA. this paper concludes by summarizing the advertising and promotion regulations set forth by the FDA during the post-approval phase.
Related Concept Videos
Drug Regulation
FDA Approved Drugs: Changes to Approved Drugs
Clinical Trials: Overview
Preclinical Development: Overview
Drug Products: Biologics, Biosimilars and Interchangeables
Drug Control Governance: Regulatory Bodies and Their Impact
